tetano
Editor, Senior Moderator
Microbiol Spectr
. 2024 Feb 13:e0307423.
doi: 10.1128/spectrum.03074-23. Online ahead of print. Accurate detection of influenza A virus by use of a novel cross-priming isothermal amplification-based point-of-care assay
Jiankai Deng[SUP] #[/SUP][SUP] 1 [/SUP], Hongji Zhu[SUP] #[/SUP][SUP] 1 [/SUP], Shu An[SUP] 1 [/SUP], Hao Huang[SUP] 1 [/SUP], Ruizhi Wang[SUP] 1 [/SUP], Yaoming Chen[SUP] 1 [/SUP], Peisong Chen[SUP] 1 [/SUP], Xuegao Yu[SUP] 1 [/SUP]
Affiliations
Influenza virus is known to cause respiratory tract infections of varying severity in individuals of all ages. The EasyNAT Rapid Flu assay is a newly developed in vitro diagnostic test that employs cross-priming isothermal amplification (CPA) to detect and differentiate influenza A and B viruses in human nasopharyngeal (NP) swabs. The aim of this study is to determine the performance characteristics of the EasyNAT Rapid Flu assay for rapid detection of influenza virus. The limit of detection (LOD) and cross-reactivity of the EasyNAT Rapid Flu assay were assessed. The clinical performance of the assay was evaluated using NP swab samples that were tested with real-time reverse-transcription polymerase chain reaction (RT-PCR) and Xpert Xpress Flu/RSV assay. The LOD for the detection of influenza A and B using the EasyNAT Rapid Flu assay was found to be 500 copies/mL. Furthermore, the assay exhibited no cross-reactivity with other common respiratory viruses tested. For the 114 NP swab samples tested for influenza A using both the EasyNAT Rapid Flu assay and real-time RT-PCR, the two assays demonstrated a high level of agreement (κ = 0.963, P < 0.001), with a positive percentage agreement (PPA) of 97.7% and a negative percentage agreement (NPA) of 98.6%. Similarly, for the 43 NP swab samples tested for influenza A and B using both the EasyNAT Rapid Flu assay and Xpert Xpress Flu/RSV assay, the two assays showed a high level of agreement (κ = 0.933, P < 0.001), with the overall rate of agreement (ORA) of 97.7% for influenza A and 100% for influenza B. The EasyNAT Rapid Flu assay demonstrates excellent performance in the detection of influenza A, highlighted by its strong agreement with RT-PCR-based assays.IMPORTANCEThe newly developed EasyNAT Rapid Flu assay is an innovative cross-priming isothermal amplification-based method designed for detecting influenza A and B viruses at point-of-care settings. This study aims to thoroughly assess the analytical and clinical performance of the assay, offering valuable insights into its potential advantages and limitations. The findings of this research hold significant implications for clinical practice.
Keywords: Xpert Xpress Flu/RSV assay; cross-priming isothermal amplification; influenza virus; point-of-care; real-time RT-PCR.
. 2024 Feb 13:e0307423.
doi: 10.1128/spectrum.03074-23. Online ahead of print. Accurate detection of influenza A virus by use of a novel cross-priming isothermal amplification-based point-of-care assay
Jiankai Deng[SUP] #[/SUP][SUP] 1 [/SUP], Hongji Zhu[SUP] #[/SUP][SUP] 1 [/SUP], Shu An[SUP] 1 [/SUP], Hao Huang[SUP] 1 [/SUP], Ruizhi Wang[SUP] 1 [/SUP], Yaoming Chen[SUP] 1 [/SUP], Peisong Chen[SUP] 1 [/SUP], Xuegao Yu[SUP] 1 [/SUP]
Affiliations
- PMID: 38349165
- DOI: 10.1128/spectrum.03074-23
Influenza virus is known to cause respiratory tract infections of varying severity in individuals of all ages. The EasyNAT Rapid Flu assay is a newly developed in vitro diagnostic test that employs cross-priming isothermal amplification (CPA) to detect and differentiate influenza A and B viruses in human nasopharyngeal (NP) swabs. The aim of this study is to determine the performance characteristics of the EasyNAT Rapid Flu assay for rapid detection of influenza virus. The limit of detection (LOD) and cross-reactivity of the EasyNAT Rapid Flu assay were assessed. The clinical performance of the assay was evaluated using NP swab samples that were tested with real-time reverse-transcription polymerase chain reaction (RT-PCR) and Xpert Xpress Flu/RSV assay. The LOD for the detection of influenza A and B using the EasyNAT Rapid Flu assay was found to be 500 copies/mL. Furthermore, the assay exhibited no cross-reactivity with other common respiratory viruses tested. For the 114 NP swab samples tested for influenza A using both the EasyNAT Rapid Flu assay and real-time RT-PCR, the two assays demonstrated a high level of agreement (κ = 0.963, P < 0.001), with a positive percentage agreement (PPA) of 97.7% and a negative percentage agreement (NPA) of 98.6%. Similarly, for the 43 NP swab samples tested for influenza A and B using both the EasyNAT Rapid Flu assay and Xpert Xpress Flu/RSV assay, the two assays showed a high level of agreement (κ = 0.933, P < 0.001), with the overall rate of agreement (ORA) of 97.7% for influenza A and 100% for influenza B. The EasyNAT Rapid Flu assay demonstrates excellent performance in the detection of influenza A, highlighted by its strong agreement with RT-PCR-based assays.IMPORTANCEThe newly developed EasyNAT Rapid Flu assay is an innovative cross-priming isothermal amplification-based method designed for detecting influenza A and B viruses at point-of-care settings. This study aims to thoroughly assess the analytical and clinical performance of the assay, offering valuable insights into its potential advantages and limitations. The findings of this research hold significant implications for clinical practice.
Keywords: Xpert Xpress Flu/RSV assay; cross-priming isothermal amplification; influenza virus; point-of-care; real-time RT-PCR.